Shionogi & Company Description
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes.
It has a research and license option agreement with BioVersys AG to develop novel ansamycin leads from BV500 program into clinical candidates.
The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943.
Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
| Country | Japan |
| Founded | 1878 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,955 |
| CEO | Isao Teshirogi |
Contact Details
Address: 1-8, Doshomachi 3-chome Osaka, 541-0045 Japan | |
| Phone | 81 6 6202 2161 |
| Website | shionogi.com |
Stock Details
| Ticker Symbol | SGIOY |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | US8246671098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Isao Teshirogi Ph.D. | Chief Executive Officer, President and Representative Director |
| Takuji Fujiwara | Accounting and Finance Manager |
| Takeshi Shiota Ph.D. | Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics and Compliance Management Div. |
| Yoshimasa Kyokawa | Vice President of Corporate Communications and Secretary Office |
| Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office |
| Koji Hanasaki Ph.D. | Senior Executive Officer |
| Dr. John A. Keller Ph.D. | Senior Executive Officer and SVice President of Research & Development Supervisory Unit and Pharma. Tech. Research Div. |
| Kazuhiro Hatanaka | Senior Executive Officer and Senior Vice President of Corporate Supervisory Unit |
| Akira Kato Ph.D. | Senior Executive Officer and Senior Vice President of Supply Supervisory Unit |
| Toshinobu Iwasaki Ph.D. | Senior Executive Officer and Senior Vice President of Healthcare Business Supervisory Unit |